MSA
BIIB icon

Marino Stram & Associates’s Biogen BIIB Stock Holding History

Marino Stram & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,048
Closed -$363K – 159
2021
Q2 		$363K Buy
+1,048
New +$317K 0.09% 171
2019
Q2 		– Sell
-39
Closed -$9K – 133
2019
Q1 		$9K Buy
39
+2
+5% +$630 0.01% 310
2018
Q4 		$11K Hold
37
– – 0.01% 264
2018
Q3 		$13K Buy
+37
New +$12.7K 0.01% 274

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marino Stram & Associates's BIIB Position: Q3 2021 in Review

Marino Stram & Associates sold out of Biogen (BIIB) in Q3 2021, closing a stake of 1,048 shares — an estimated $363K sold.

Marino Stram & Associates first reported a position in BIIB in Q3 2018 and held it in 4 quarters. The position peaked at $363K in Q2 2021. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

  • Marino Stram & Associates reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
  • Marino Stram & Associates sold 1,048 Biogen shares in Q3 2021, an estimated $363K.
  • Marino Stram & Associates first reported a position in Biogen in Q3 2018 and held it in 4 quarters.
  • Marino Stram & Associates's Biogen position peaked at $363K in Q2 2021.
  • 1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Marino Stram & Associates's 13F filing for Q3 2021, filed 14 Oct 2021.